BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yip TC, Lok AS. How Do We Determine Whether a Functional Cure for HBV Infection Has Been Achieved? Clin Gastroenterol Hepatol 2020;18:548-50. [PMID: 31446185 DOI: 10.1016/j.cgh.2019.08.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Jeng WJ, Lok ASF. What will it take to cure hepatitis B? Hepatol Commun 2023;7:e0084. [PMID: 36972391 DOI: 10.1097/HC9.0000000000000084] [Reference Citation Analysis]
2 Svicher V, Salpini R, D’anna S, Piermatteo L, Iannetta M, Malagnino V, Sarmati L. New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1143258] [Reference Citation Analysis]
3 Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K, Martin R, Aeschbacher T, Suri V, Tan SK, Feierbach B, Gaggar A, Marcellin P, Buti Ferret M, Janssen HLA, Gane E, Meagher N, Price DJ, Wong D, Thompson AT, Revill PA. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B. Aliment Pharmacol Ther 2023;57:509-23. [PMID: 36427857 DOI: 10.1111/apt.17299] [Reference Citation Analysis]
4 Yip TC, Wong VW, Lai MS, Lai JC, Hui VW, Liang LY, Tse YK, Chan HL, Wong GL. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J Hepatol 2023;78:524-33. [PMID: 36463985 DOI: 10.1016/j.jhep.2022.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liang LY, Wong VW, Wong GL, Yip TC. Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers. Clin Mol Hepatol 2023;29:113-7. [PMID: 36314042 DOI: 10.3350/cmh.2022.0333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C. Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment. J Viral Hepat 2021;28:1539-44. [PMID: 34363715 DOI: 10.1111/jvh.13592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
8 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kim HN. Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy. Curr Hepatol Rep 2020;19:345-53. [PMID: 33796434 DOI: 10.1007/s11901-020-00541-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]